Introduction

Tinea pedis is a dermatophyte fungus infection that affects the foot (Li et al., 2014). According to Li et al. (2014), the infection has increasingly become common due to the changing lifestyle. The infection thrives well in humid and warm conditions in adult men. It is often as a result of the Trichophyton (T.) rubrum. According to Hiroyasu et al. (2012), dermatophytosis is a common infection that is found in the superficial mycoses. The reason for the most unsuccessful use of the antifungal management methods is due to the skin relapse due to the poor adherence to the terms of treatment required in the use of the tropical antifungal medications (Hiroyasu et al., 2012). The treatment of the tinea pedis has received many attempts in terms of the compounded medications and the convention therapies.

Using the compound tropical anti-fungal treatment medications has shown positive results across many patients. Despite the success of each of the method, there are also health side effects of the anti-fungal pills on the body of the patients while treating the tinea pedis. Some of the compounded tropical anti-fungal drugs include the luliconazole, fluconazole, eberconazole, terbinafine and amorolfine (Goldstein and Goldstein, 2017). While treating the tinea pedis fungal disease, the body is equally exposed to health effects such as burning, skin peeling, itching, hyperpigmentation and irritation (Hiroyasu et al., 2012). Other side effects include the body redness, pain, heat sensation, eczema, pruritus and erythema. Hiroyasu et al. (2012) also reported that the use of the compounded drugs such as terbinafine to treat the fungal infections has health effects on the body. Even though the use of the luliconazole has side effects, they cannot prevent or stop administration of the dosage.

            The fact that the use of the conventional therapies has remained ineffective brings a positive light to the use of the compound tropical medications. It, therefore, be hypothesized that the use of the compound tropical antifungal drugs has significant effect in the treatment of the tinea pedis. The application of the conventional therapy to treat the tinea pedis is unreliable since it has high resistance to antifungal therapy when applied solely to therapy (CANDIDIASIS, 2008).

The compound tropical medications offer a lot of benefits like customizable dosages, multiple drug combination, reduced risks of pills abuse and lack of addiction among others (Sahoo and Mahajan, 2016; Branvold and Carvalho, 2014). The choice of anti-fungal treatments depends on the susceptibility of the therapy or the drug being used (Risslegger, Lass-Flörl, Blum and Lackner, 2015). Therefore, the susceptibility of the antifungal tropical is an aspect that needs in-depth consideration during the treatment of the tinea pedis feet infections (Scientific, 2009).

People with diabetes and infections of the onychomycosis can use the compounded medicines such as the terbinafine and the itraconazole to treat the condition. From a study, it was concluded that the use of the compound antifungals in the treatment of patients with tinea pedis is effective than the use of the conventional therapy which is characterized by relapse (Matricciani, Talbot and Jones, 2011). The terbinafine can also be used in combination with other antifungal drugs to improve the effectiveness of the treatment of the tinea pedis (Dolton, Perera, Pont and McLachlan, 2014). Only 1% is enough to show efficacy and effectiveness in the treatment of the fungal foot infection. Finally, the ingredients of the compounded antifungal tropical drugs vary with the target condition. According to Cada and Baker (2014), hormones such as the estrogen can also be used to make the compound antifungals and has shown effectiveness among the menopause age groups. The terbinafine can be prepared from the ethosomes and hydrochloride.  Therefore, this paper puts forward  that compounded tropical anti-fungal medications offer safe treatment of the tinea pedis.

References

Koga, Hiroyasu et al. “Short-Term Therapy with Luliconazole, a Novel Topical Antifungal Imidazole, in Guinea Pig Models of Tinea Corporis and Tinea Pedis.” Antimicrobial Agents and Chemotherapy 56.6 (2012): 3138–3143. PMC. Web. 20 Feb. 2018.

Branvold, A., & Carvalho, M. (2014). Pain management therapy: The benefits of compounded transdermal pain medication. Journal of General Practice.

Risslegger, B., Lass-Flörl, C., Blum, G., & Lackner, M. (2015). Evaluation of a Modified EUCAST Fragmented-Mycelium Inoculum Method for In VitroSusceptibility Testing of Dermatophytes and the Activity of Novel Antifungal Agents. Antimicrobial Agents and Chemotherapy, 59(6), 3675–3682. http://doi.org/10.1128/AAC.04381-14

Scientific Abstracts. (2009). Journal of General Internal Medicine, 24(Suppl 1), 1–380. http://doi.org/10.1007/s11606-009-0963-3

Sahoo, A. K., & Mahajan, R. (2016). Management of tinea corporis, tinea cruris, and tinea pedis: A comprehensive review. Indian dermatology online journal, 7(2), 77.

CANDIDIASIS, M. (2008). Antifungal agents for common paediatric infections. Can J Infect Dis Med Microbiol, 19(1), 15.

Goldstein, A. O., & Goldstein, B. G. (2017). Dermatophyte (tinea) infections. Walthman, MA: UpToDate.

Matricciani, L., Talbot, K., & Jones, S. (2011). Safety and efficacy of tinea pedis and onychomycosis treatment in people with diabetes: a systematic review. Journal of foot and ankle research, 4(1), 26.

Dolton, M. J., Perera, V., Pont, L. G., & McLachlan, A. J. (2014). Terbinafine in Combination with Other Antifungal Agents for Treatment of Resistant or Refractory Mycoses: Investigating Optimal Dosing Regimens Using a Physiologically Based Pharmacokinetic Model. Antimicrobial Agents and Chemotherapy, 58(1), 48–54. http://doi.org/10.1128/AAC.02006-13

Li, R. Y., Wang, A. P., Xu, J. H., Xi, L. Y., Fu, M. H., Zhu, M., … Gong, Z. Q. (2014). Efficacy and Safety of 1 % Terbinafine Film-Forming Solution in Chinese Patients with Tinea Pedis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study. Clinical Drug Investigation, 34(3), 223–230. http://doi.org/10.1007/s40261-014-0171-8

Cada, D. J., & Baker, D. E. (2014). Conjugated Estrogens and Bazedoxifene. Hospital Pharmacy, 49(3), 273–283. http://doi.org/10.1310/hpj4903-273

This entry was posted on March 4, 2018 at 9:15 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.